Related to Merck KGaA and Lonza Separately Acquire Indian Bioscience Companies

• Chicago Plans Biotech Commercialization Center
  
• Ascletis Obtains Chinese Rights to Janssen HIV Treatment
  
• Oncobiologics Finds Partner to Launch Biosimilars in U.S., China
  
• Amgen Forms Joint Venture to Sell Vectibix in China
  
• Vectura, Chinese Partners Form $65M Respiratory JV
  
• RuiYi Licenses mAb Development to China's Genor
  
• Mundipharma to Market Novelos' Phase III Lung Cancer Drug in Europe and Asia through Deal Worth $95M
  
• Access Pharmaceuticals Grants JCOM Korean License to Two Cancer Products
  
• IRI Intends to Partner with PharmaFoods to Produce Helicobacter Pylori and Avian Influenza Antibodies
  
• Immtech Considers an Alliance with Beijing Pharmaceutical
  
• Mitsubishi Tanabe Expands Commercial Rights to Vertex’ HCV Candidate with $105M Up Front
  
• S-Evans Biosciences Gains Chinese Rights to Cryo-Cell’s Menstrual Stem Cell Technology
  
• Lonza Raises the Stakes on JLL’s Push to Take Over Patheon
  
• Ono Gains Rights to Tioga’s IBS Therapy in Japan, South Korea, and Taiwan
  
• International Institute of Biomedical Sciences and Technology Has Been Formed by Institutes in NY, Israel, and Taiwan
  
• Corning Puts Down $400M for Axygen to Expand Consumables Portfolio and Presence in Asia
  
• GSK Furthers Interest in China through Pediatric Vaccines JV with Initial $32M Investment
  
• Lonza Takes Equity Stake in Ciliate-Expression System Company
  
• Nacalai Gains Distribution Rights to  LifeSensors’ Products in Asian Market
  
• CLC bio to Provide Next-Generation Sequencing Solutions in Japan Through Filgen